Eli Lilly Inks $1.26 Billion Deal for South Korean Digestive Disease Treatment
Seoul, Monday, 1 June 2026.
In late May 2026, Eli Lilly committed up to $1.26 billion for Hanmi Pharmaceutical’s digestive drug candidate, sparking a nearly 17 percent surge in the South Korean biotech’s shares.
A Strategic Leap into Gastrointestinal Innovation
In late May 2026, U.S. pharmaceutical giant Eli Lilly and Company [GPT] entered into an exclusive licensing agreement with South Korea’s Hanmi Pharmaceutical Co., Ltd. (KRX: 128940) [3][4]. The deal, which grants Lilly worldwide rights to the drug candidate sonefpeglutide—excluding the South Korean market—carries a total potential value of up to USD 1.26 billion, or approximately 1.9 trillion South Korean won [1][2][4][5]. Hanmi is set to receive an upfront cash payment of USD 75 million [1][2][4][5]. Furthermore, the Seoul-based drugmaker is eligible for up to USD 1.185 billion in milestone payments tied to clinical development, regulatory approvals, and commercialization, alongside post-launch sales royalties [1][2][4][5].
Market Dynamics and the Short Bowel Syndrome Landscape
Eli Lilly’s strategic investment underscores a calculated push into a highly specialized medical market [2]. Currently, the only globally approved treatment for short bowel syndrome is “Gattex,” manufactured by Takeda Pharmaceutical [2]. Gattex commands a significant market presence, generating approximately 1 trillion won in annual sales [2]. By securing the rights to Hanmi’s GLP-2 candidate, Lilly is positioning itself to capture a substantial share of this lucrative, underserved therapeutic area [2]. Industry observers interpret the substantial financial commitment as a strong validation of both the drug’s clinical potential and Hanmi’s underlying platform technology [2].
Division of Labor and Future Clinical Pathways
Operationally, the agreement establishes a clear division of responsibilities moving forward [1][2][4]. Hanmi Pharmaceutical will retain control over the ongoing global Phase 2 clinical trial for short bowel syndrome until its completion [1][2][4][5]. Once this phase concludes, Eli Lilly will assume full responsibility for all subsequent clinical development, manufacturing processes, and global commercialization efforts [1][2][4][5]. Additionally, Lilly plans to utilize the newly acquired preclinical and clinical data to explore expanding the drug’s indications beyond short bowel syndrome [1][2][4].